Nachrichten zur AstraZeneca PLC Aktie

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in einer abschließenden klinischen Studie (Phase-III) mit Lungenkrebs-Patienten…

05 April 2024 Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase…

FDA approves AstraZenecas (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck…

AstraZenecas (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase…

2 April 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

2 April 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast…

AstraZenecas (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.…

FDA approves AstraZenecas (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult…

…

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9500 Pence…

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation…

AstraZeneca CEO Pascal Soriot discusses the drugmaker’s business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships…

The chief executive officers of AstraZeneca Plc and Pfizer Inc. pledged to support expansion of China’s biopharmaceutical industry, even as…

FDA approves AstraZenecas (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved…

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9900…

AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower…

AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of…

AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value…

…

…

The company is working on radiopharmaceuticals treatments for cancer.…

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…

AstraZeneca PLC (LSE:AZN) is acquiring Canadas Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively keep up with Joneses…

The deal is AstraZenecas second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to…

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca will den kanadischen Krebsspezialisten Fusion Pharmaceuticals übernehmen. Dabei…

…

AstraZeneca Plc agreed to buy Fusion Pharmaceuticals Inc. for as much as $2.4 billion as it seeks to transform cancer…

HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Astrazeneca von 12500 auf…

NEW YORK (dpa-AFX Broker) - Die US-Bank JPMorgan hat Astrazeneca auf "Overweight" mit einem Kursziel…

FRANKFURT (dpa-AFX Broker) - Deutsche Bank Research hat Astrazeneca nach Zahlen von "Hold" auf "Sell"…

CAMBRIDGE (dpa-AFX) - Ein gutes Geschäft mit Krebsmedikamenten gleicht bei Astrazeneca den Umsatzschwund mit Covid-Produkten…